在24个月的随访期内，比较玻璃体内注射雷珠单抗治疗典型新生血管性年龄相关性黄斑变性和息肉状脉络膜血管病变的有效性及预后因素。

Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up.

作者信息

Matsumiya Wataru, Honda Shigeru, Otsuka Keiko, Miki Akiko, Nagai Takayuki, Imai Hisanori, Kusuhara Sentaro, Nakamura Makoto

机构信息

Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.

出版信息

Ophthalmologica. 2015;234(1):33-9. doi: 10.1159/000431000. Epub 2015 Jun 20.

DOI:10.1159/000431000

PMID:26112059

Abstract

PURPOSE

To compare the response to ranibizumab between patients with typical neovascular age-related macular degeneration (tAMD) and those with polypoidal choroidal vasculopathy (PCV), and to determine the predictors for the outcomes.

METHODS

Fifty-nine eyes from 59 consecutive patients (tAMD: 27 eyes, PCV: 32 eyes) were treated with three monthly ranibizumab injections followed by as-needed retreatment. Best-corrected visual acuity (BCVA) and morphological parameters were evaluated over 24 months of follow-up.

RESULTS

The mean BCVA in tAMD and PCV patients was significantly improved at 3 months (-0.22 and -0.09 logMAR units, respectively). The improvement in BCVA was sustained up to 24 months in tAMD (p = 0.01) but not in PCV patients. The significant predictor for good response to ranibizumab in tAMD patients was the improvement of BCVA at 3 months, whereas that in PCV patients was the anatomical resolution at 3 months.

CONCLUSIONS

Ranibizumab is an effective therapy for tAMD and PCV over 24 months. The predictors for good outcome might be different between tAMD and PCV.

摘要

目的

比较典型新生血管性年龄相关性黄斑变性（tAMD）患者与息肉状脉络膜血管病变（PCV）患者对雷珠单抗的反应，并确定预后的预测因素。

方法

对59例连续患者的59只眼（tAMD：27只眼，PCV：32只眼）进行治疗，每月注射雷珠单抗3次，随后根据需要进行再次治疗。在24个月的随访期间评估最佳矫正视力（BCVA）和形态学参数。

结果

tAMD和PCV患者的平均BCVA在3个月时均有显著改善（分别为-0.22和-0.09 logMAR单位）。tAMD患者的BCVA改善持续至24个月（p = 0.01），而PCV患者则未持续改善。tAMD患者对雷珠单抗反应良好的显著预测因素是3个月时BCVA的改善，而PCV患者则是3个月时的解剖学缓解。